Literature DB >> 8801866

Abnormal lipoprotein phospholipid composition in patients with essential hypertension.

J D Bagdade1, W F Buchanan, T Pollare, H Lithell.   

Abstract

Vascular cell membranes from patients with essential hypertension (EH) and animals with genetic forms of hypertension have been found to have alterations in the content of free cholesterol and negatively charged phospholipids that may modify their function. Since membrane and lipoprotein lipids exchange freely, the lipid composition of lipoproteins may be an indirect measure of the content of vascular and other cells. To determine whether abnormalities are present in the lipid and phospholipid composition of lipoproteins from patients with EH, 30 EH (11 women; 19 men) and 20 normotensive control subjects were studied. Since significant gender differences were present in a number of parameters of lipoprotein composition, male and female data were examined separately. The EH group of both sexes tended to have higher plasma TG and VLDL + LDL and HDL2 lipid levels than their respective controls. Not only were the calcium-binding phospholipids phosphatidylinositol (PI) + phosphatidylserine (PS), and the membrane fluidizer phosphatidylethanolamine (PE) were significantly reduced in their VLDL + LDL, but all phospholipids (L, sphingomyelin (SPH), PI + PS, and PE) were significantly reduced in their neutral lipid content in both the HDL2 and HDL3 subfractions. These directional changes in lipoprotein FC and phospholipid in the EH women significantly increased the EH FC/PC (mol/mol) ratio in their plasma, a new cardiovascular risk factor, (EH 1.08 +/- 0.22 vs. control 0.86 +/0 0.08; P < 0.01) and lowered the SPH/PC ratio HDL2 and HDL3 in EH patients of both sexes. These findings showed that lipoproteins in normolipidemic EH women are relatively enriched in FC and in EH patients of both sexes depleted in certain phospholipids lacking in lipoproteins, their functional properties could be altered and vascular tone increased.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8801866     DOI: 10.1016/0021-9150(95)05573-f

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension.

Authors:  J D Bagdade; W F Buchanan; T Pollare; H Lithell
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Alterations in heart and kidney membrane phospholipids in hypertension as observed by 31P nuclear magnetic resonance.

Authors:  Y Chi; R K Gupta
Journal:  Lipids       Date:  1998-10       Impact factor: 1.880

Review 3.  Dysfunctional high-density lipoprotein.

Authors:  Hong Feng; Xiang-An Li
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

4.  Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension.

Authors:  Mogens Fenger; Allan Linneberg; Torben Jørgensen; Sten Madsbad; Karen Søbye; Jesper Eugen-Olsen; Jørgen Jeppesen
Journal:  BMC Genet       Date:  2011-05-13       Impact factor: 2.797

5.  A phospholipidomic analysis of all defined human plasma lipoproteins.

Authors:  Monireh Dashti; Willem Kulik; Frans Hoek; Enno C Veerman; Maikel P Peppelenbosch; Farhad Rezaee
Journal:  Sci Rep       Date:  2011-11-07       Impact factor: 4.379

Review 6.  Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within.

Authors:  Sarina Kajani; Sean Curley; Fiona C McGillicuddy
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

7.  An untargeted metabolomics study of blood pressure: findings from the Bogalusa Heart Study.

Authors:  William J He; Changwei Li; Xuenan Mi; Mengyao Shi; Xiaoying Gu; Lydia A Bazzano; Alexander C Razavi; Jovia L Nierenberg; Kirsten Dorans; Hua He; Tanika N Kelly
Journal:  J Hypertens       Date:  2020-07       Impact factor: 4.844

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.